Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral poliovirus vaccine types 1 and 3
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Bivalent oral poliovirus vaccine (bOPV) is a live attenuated vaccine containing Sabin strains of poliovirus types 1 and 3. It is indicated for active immunization against poliomyelitis caused by these two serotypes. The vaccine was introduced globally in 2016 as part of a coordinated switch to replace the trivalent oral polio vaccine (tOPV) following the eradication of wild poliovirus type 2. It contains attenuated Sabin strains (Type 1: LSc, 2ab; Type 3: Leon 12a, 1b) propagated in human diploid cells (MRC-5) and stabilized with magnesium chloride. The vaccine induces both mucosal and systemic immunity, mimicking a natural infection to provide protection against paralytic poliomyelitis.
- Brand names
- Polio Sabin One and Three
- Other names
- bivalent oral polio vaccinebOPV types 1 and 3poliomyelitis vaccine, live, oral, bivalent
02
Targets
PVR
Beyond the preview
Go deeper on bivalent oral poliovirus vaccine types 1 and 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral poliovirus vaccine types 1 and 3.